<DOC>
	<DOCNO>NCT01146080</DOCNO>
	<brief_summary>Compared bare metal stent ( BMS ) , paclitaxel-eluting stent ( PES ) sirolimus-eluting stent ( SES ) significantly reduce angiographic restenosis need repeat revascularization coronary artery across broad range patient lesion type . However increase risk late stent thrombosis represent major concern patient treat PES SES . Optical coherence tomography ( OCT ) , new image technique base back reflection near infrared light , enable real-time , full tomographic , in-vivo visualization coronary vessel microstructure . Struts coverage vessel response drug elute stent ( DES ) compare BMS immediate clinical application OCT. Thickness coverage strut apposition quantify micron-scale level resolution 10-30 time higher conventional intravascular ultrasound ( IVUS ) . The objective study OCTEVEREST ( Optical Coherence Tomography EVERolimus Eluting STent ) evaluate long term strut coverage vessel wall response ( abnormal intraluminal defect , strut malapposition , vessel expansion ) PROMUS™ Everolimus Eluting Stent compare PROMUS ELEMENT™ Everolimus Eluting Stent implant treatment stenosis native coronary . To investigate completeness strut coverage well proportion malapposed strut neointima characteristic , high resolution ( ~ 10 µ axial ) intracoronary Optical Coherence Tomography ( OCT ) intravascular coronary ultrasound ( IVUS ) use .</brief_summary>
	<brief_title>Optical Coherence Tomography EVERolimus Eluting STent</brief_title>
	<detailed_description>This prospective single center clinical study design evaluate long term strut coverage vessel wall response ( abnormal intraluminal defect , strut malapposition , vessel espansions ) PROMUS™ Everolimus Eluting Stent compare PROMUS ELEMENT ™ Everolimus Eluting Stent implant treatment stenosis native coronary . The difference two stent stent platform make novel alloy chromium-platinum low strut thickness stent cross profile ( 0.042 '' [ 1.062 mm ] ) PROMUS ELEMENT ™ Everolimus Eluting Stent . To investigate completeness strut coverage well proportion malapposed strut neointima characteristic , high resolution ( ~ 10 µ axial ) intracoronary Optical Coherence Tomography ( OCT ) intravascular coronary ultrasound ( IVUS ) use . The study carry Ospedali Riuniti di Bergamo , Italy target enrollment consecutive 21 patient group receive one two Everolimus Eluting stent . All patient enrol study follow 12 month post stent placement . PLATFORM TO BE USED PROMUS™ everolimus elute stent . Stent size : 2.5 3.5 mm , 12 - 15 - 20 - 23 - 28 mm length ( accord product specification ) . PROMUS ELEMENT ™ Everolimus Eluting Stent . Stent size : 2.5 3.5 mm , 12 - 15 -20 - 23 - 28 mm length ( accord product specification ) . Patients present coronary artery lesion consider candidate percutaneous coronary intervention stent placement eligible OCTEVEREST ( Optical Coherence Tomography EVERolimus Eluting STent ) trial . Patients may second study lesion treat second PROMUS™ Stent PROMUS ELEMENT ™ Everolimus Eluting Stent . Patients meet inclusion/exclusion criterion enrol follow study . All patient candidate OCTEVEREST trial undergo placement device must consent prior data collection member institution 's research team . All patient enrol evaluated accord protocol , regardless sequence treatment ensues . More one study lesion different epicardial vessel may treat stage procedure . Actual study enrollment occur follow successful pre-dilatation study vessel , study device introduce body . The target lesion must able cover single stent . For diffuse lesion total lesion length measure proximal shoulder proximal lesion distal shoulder distal lesion exceed 24 mm . At 6 month follow-up , entire stented region use determine mean lumen diameter percent diameter stenosis . Optical coherence tomography ( OCT ) perform baseline 6 month follow . Study site request use OCT equipment procedure . The OCT procedure conduct accord Optical Coherence Tomography specify Protocol . Optical Coherence Tomography image acquire 15-30 frame per second ( 500 angular pixel x 250 radial pixel ) , 0.006 '' micro-optic core , 0.014 '' image wire , displayed inverse gray-scale lookup table , digitally archive . The optical source use study center wavelength 1310 nm bandwidth 70 nm , provide axial resolution ( 10-12 μm tissue tissue penetration 2 mm ) . The transverse resolution , determine spot size sample arm beam , 25 μm . OCT image analyze independent Corelab ( Cardialysis , Cleveland ) expert high resolution OCT analysis . An automatic analysis novel dedicate software use quantitative assessment . Interactive revision contour appropriateness perform experienced reader . In blind fashion 10 % section re-evaluated estimate measurement variability ( k value ) . The existence malapposition assess . Angiography Angiography perform baseline prior stent placement , stent placement , 6 month follow . The Angiography procedure conduct accord Angiographic Core Laboratory procedure .A baseline angiography involve vessel perform least two near orthogonal view . Visual angiographic assessment use determine lesion meet angiographic entry criterion . The study lesion must free foreshorten vessel overlap . If angiography demonstrate target lesion meet study eligibility criterion , patient may enrol study . Intravascular Ultrasound IVUS perform time index procedure 6 month follow . IVUS initially perform successful , uncomplicated stent implantation ( diameter stenosis &lt; 10 % , TIMI-3 flow ) . Study site IS request use IVUS equipment procedure . IVUS perform patient accord IVUS Core . Laboratory Acquisition Protocol . Imaging perform 40 MHz Atlantis catheter ( Boston Scientific ) , 50- 200 mcg intracoronary nitroglycerin . Automated motorize pullback 0.5 mm/sec utilized IVUS run ( Hi-Lab Boston Scientific ) . Imaging include edge least 5 mm proximal distal stent . The transducer advance least 10 mm distal distal edge stent ( ) , continuous , uninterrupted imaging run perform point least 10mm proximal proximal edge stent ( ) . All IVUS study archive subsequent CoreLab analysis DICOM format . IVUS analysis include measurement external elastic membrane ( EEM ) , stent , lumen cross-sectional area volume accord Standards Acquisition , Measurement , Reporting Intravascular Ultrasound Studies . In addition , qualitative analysis ( incomplete apposition , dissection ) also perform accord standard document .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient ≥ 18 year age Patient eligible percutaneous coronary intervention ( PCI ) Patient document stable angina pectoris ( Canadian Cardiovascular Society [ CCS ] Classification 1 , 2 , 3 , 4 ) document silent ischemia ; unstable angina pectoris ( Braunwald Class IBC , IIBC , IIIBC ) Patient demonstrate leave ventricular ejection fraction ( LVEF ) ≥ 40 % measure prior enrollment Patient understand agree comply specify study requirement provide write Informed Consent effect . Angiographic Inclusion Criteria Target lesion must locate native coronary artery visually estimate reference vessel diameter ( RVD ) ≥ 2.50 mm ≤ 3,75 mm . Target lesion length must measure ( visual estimate ) ≤ 24 mm . Target lesion must major coronary artery branch visually estimate stenosis ≥ 50 % &lt; 100 % TIMI flow &gt; 1 . 1 . General Exclusion Criteria The patient life expectancy le 24 month due another medical condition Patient history hypersensitivity everolimus paclitaxel structurally related compound Patient exhibit cardiogenic shock ( systolic pressure &lt; 80mm Hg PCWP &gt; 20mm Hg cardiac index &lt; 1.8 liters/minute/m2 intraaortic balloon pump intravenous inotropes need maintain systolic pressure &gt; 80 mm Hg ) time within 24 hour prior index procedure Patient demonstrate evidence acute chronic renal dysfunction ( serum creatinine &gt; 2.0 mg/dl 177 μmol/l ) Planned cardiac surgery procedure ≤ 6 month postindex procedure Patient demonstrate evidence acute myocardial infarction ( eg . STEMI enzyme elevation CK &gt; 2X local laboratory 's ULN unless CKMB &lt; 2X ULN ) 7 ) Cerebrovascular accident ( CVA ) include stroke TIA within previous 3 month Patient demonstrate evidence leukopenia ( leukocyte count &lt; 3.5 X 109/liter ) Patient demonstrate evidence thrombocytopenia ( platelet count &lt; 100,000/mm3 ) thrombocytosis ( &gt; 750,000/mm3 ) Patient contraindicate Aspirin ( successful prior desensitization Aspirin exclusion ) , clopidogrel , ticlopidine Patient currently warfarin , possibility treatment warfarin follow 6 month post index procedure Patient treat paclitaxel , everolimus chemotherapeutic agent within 12months prior plan index procedure Anticipated treatment paclitaxel , everolimus oral rapamycin period 6months index procedure Known allergy stainless steel Female male know intention procreate within 3 month index procedure ( due exposure paclitaxel unknown affect may fetus ) Female childbearing potential positive pregnancy test within 7 day index procedure , lactating , intend become pregnant 9 month post index procedure Patient opinion investigator clinically appropriate OCT evaluation . 2 . Angiographic Exclusion Criteria Evidence thrombus study vessel , base angiography IVUS Study lesion totally occlude ( TIMI flow ≤ 1 ) either baseline predilatation Study lesion , study vessel proximal study lesion moderately severely calcified , visual estimate Study lesion ostial location ( within 5.0 mm vessel origin ) Study lesion involve arterial segment highly tortuous anatomy lesion locate within distal &gt; 60 degree bend vessel Study lesion involve bifurcation diseased ( &gt; 50 % stenotic ) branch Left main coronary artery disease ( stenosis &gt; 50 % ) whether protect unprotected Target lesion length &gt; 24 mm , base visual estimate operator Target vessel diameter &gt; 3.75 mm , base visual estimate operator Target vessel diameter &lt; 2.5 mm base visual estimate operator Pretreatment target lesion ( exclude predilation ) another interventional device . Target lesion restenotic previous intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>drug elute stent</keyword>
	<keyword>everolimus elute stent</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>intravascular ultrasound</keyword>
</DOC>